Treatment
Docetaxel clinical trials
We’re tracking 233 recruiting studies that include Docetaxel, each written for real people, not researchers, below.
Recruiting studies
- NCT06234137Recruiting
Chemo plus targeted therapy for advanced HER2+ breast cancer
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
Wenzhou, ZhejiangAges 18–75 - NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Aurora, ColoradoAges 18 years+ - NCT05762536RecruitingPhase 2
Docetaxel or cabazitaxel with or without darolutamide
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
RotterdamAges 18 years+ - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT07747740RecruitingPhase 2
Bladder cancer treatment after BCG therapy fails
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
Moscow, MoscowAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Tucson, ArizonaAges 18 years+ - NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Birmingham, AlabamaAges 18 years+ - NCT07306624RecruitingPhase 2
Nelmastobart plus docetaxel for advanced lung cancer
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
Gyeonggi-doAges 19 years+ - NCT03919552RecruitingPhase 3
Chemoradiation with two cisplatin or carboplatin plans for nasopharyngeal cancer
This Phase 3 trial compares two chemotherapy-and-radiation combinations (cisplatin-based vs carboplatin-based) for locally advanced nasopharyngeal cancer that has not spread to distant organs. It may help researchers find which plan works best while balancing safety and effectiveness.
Guangzhou, GuangdongAges 18–64 - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Anchorage, AlaskaAges 18 years+ - NCT04136782RecruitingPhase 4
Tests two chemo drug combinations for triple-negative breast cancer
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
Harbin, HeilongjiangAges 18–70 - NCT04361708RecruitingPhase 1
Test drug combo chemotherapy for advanced pancreas and upper GI cancers
This early-phase study tests how safe and workable it is to combine irinotecan with several standard chemotherapy medicines for cancers like pancreatic and other upper GI cancers. It’s mainly looking for side effects and the best way the doses work in people with advanced or metastatic disease.
Chicago, IllinoisAges 18 years+ - NCT04437329RecruitingPhase 3
Nedaplatin vs cisplatin for nasopharyngeal cancer
This trial compares two chemotherapy drugs—nedaplatin versus cisplatin—in people newly diagnosed with a specific type of nasopharyngeal cancer. The goal is to see which drug works better and/or has a safer side-effect profile when given as part of standard treatment.
Guangzhou, GuangdongAges 18–65 - NCT04535713RecruitingPhase 2
Testing chemotherapy plus immunotherapy for advanced sarcoma
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
Santa Monica, CaliforniaAges 18 years+ - NCT04577014RecruitingPhase 1/Phase 2
Retifanlimab plus chemotherapy for advanced soft tissue sarcoma
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
New York, New YorkAges 18 years+ - NCT04840264RecruitingPhase 2
Chemotherapy for stomach cancer with blocked intestines
This Phase 2 trial tests a chemotherapy combination (docetaxel, oxaliplatin, and 5-FU) in people with stomach or gastroesophageal cancer that has spread to the lining of the abdomen and is causing an inoperable bowel blockage. It aims to shrink or control the blockage and cancer when surgery cannot be done.
Guangzhou, GuangdongAges 18–75 - NCT05184803RecruitingPhase 2
Pre-surgery chemo for advanced stomach cancer with lymph spread
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
Seoul, SeoulAges 19 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Birmingham, AlabamaAges 18 years+ - NCT05430399RecruitingPhase 3
Utidelone vs docetaxel for HER2-negative breast cancer
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Guangzhou, GangdongAges 18 years+ - NCT05638594RecruitingPhase 2
Neoadjuvant drug study for hormone- and HER2-positive breast cancer
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Shenyang, LiaoningAges 18–75 - NCT05777278RecruitingPhase 1/Phase 2
Savolitinib plus docetaxel for advanced lung cancer with high MET
This trial studies savolitinib (an oral MET-targeted medicine) combined with docetaxel (an IV chemotherapy) in people with advanced non-small cell lung cancer (NSCLC) whose tumor has high MET activity. It’s designed to see if this combination can shrink tumors or control the cancer after the first standard treatment.
Guangzhou, GuangdongAges 18 years+ - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT05983783RecruitingPhase 3
Testing two drug combinations for advanced prostate cancer
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
Nanjing, JiangsuAges 40–80 - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75
Common questions
- Are there clinical trials studying Docetaxel?
- Yes. Clin2 currently lists 233 recruiting studies that include Docetaxel, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Docetaxel trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Docetaxel an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Docetaxel or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.